BioCardia (BCDA) CEO Altman buys $700 in shares
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biocardia Inc (BCDA)
Biocardia Inc stock price live, this page displays NASDAQ BCDA stock exchange data. View the BCDA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Biocardia Inc real time stock price chart below.
What Is the Biocardia Inc Stock Price Today?
The Biocardia Inc stock price today is 1.920.
What Is the Stock Symbol for Biocardia Inc?
The stock symbol for Biocardia Inc is ""BCDA.""
What Stock Exchange Does Biocardia Inc Trade On?
Biocardia Inc is listed and trades on the NASDAQ stock exchange.
Is Biocardia Inc a Good Stock to Buy?
Determining whether Biocardia Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCDA quote. (ISIN: US09060U6064)
What Is the Biocardia Inc Stock Price Today?
The Biocardia Inc stock price today is 1.920.
What Is the Stock Symbol for Biocardia Inc?
The stock symbol for Biocardia Inc is ""BCDA.""
What Stock Exchange Does Biocardia Inc Trade On?
Biocardia Inc is listed and trades on the NASDAQ stock exchange.
Is Biocardia Inc a Good Stock to Buy?
Determining whether Biocardia Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCDA quote. (ISIN: US09060U6064)
1.920
+0.030(+1.59%)
Real-time Data·
Fair Value
An estimate of a Biocardia's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.870
1.950
52 wk Range
1.625
4.660
BCDA Scorecard
Full Analysis
Quickly burning through cash
BCDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Biocardia's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.8701.950
52 wk Range
1.6254.660
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCDA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Biocardia's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
6.000
Upside
+212.50%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Form 8K Biocardia Inc For: 16 July
- Investing.com
- Form 8K Biocardia Inc For: 4 August
- Investing.com
- BioCardia (BCDA) CEO Altman buys $700 in shares
- Investing.com
- Form 8K Biocardia Inc For: 4 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Biocardia Inc Company Profile
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system. BioCardia, Inc. is based in Sunnyvale, California.
Biocardia Inc SWOT Analysis
Pivotal Trial Phase | BioCardia's CardiAMP cell therapy system enters critical Phase 3 trial, with potential to revolutionize heart failure treatment amid financial challenges |
Regulatory Milestones | FDA protocol amendment and CMS reimbursement approval boost CardiAMP HF II trial, expanding patient eligibility and mitigating study costs |
Market Dynamics | Explore BioCardia's position in the competitive cell therapy landscape, with promising early results setting high expectations for cardiovascular treatment |
Financial Outlook | Analysts project trial completion by 2025, with price targets ranging from $4 to $25, despite current negative EBITDA and cash burn concerns |
Biocardia Inc Earnings Call Summary for Q2/2025
- BioCardia reports Q2 2025 net loss of $2M, up from $1.6M YoY; stock falls 6.15% to $1.79
- R&D expenses increase to $1.4M from $800K YoY; cash reserves at $1.1M with additional financing expected
- CardiAmp Heart Failure II trial actively enrolling; regulatory submissions to FDA and Japan's PMDA in progress
- CEO highlights efficient capital use with $6M annual burn rate; company exploring partnerships for technological platforms
- Planned FDA submission for Helix Biotherapeutic Delivery System in Q3 2025; PMDA meeting scheduled for mid-Q4 2025
Last Updated: 11/08/2025, 22:30
Read Full TranscriptCompare BCDA to Peers and Sector
Metrics to compare | BCDA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCDAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −3.2x | −0.5x | |
PEG Ratio | −0.02 | 0.02 | 0.00 | |
Price/Book | −5.9x | 0.4x | 2.6x | |
Price / LTM Sales | - | 8.5x | 3.3x | |
Upside (Analyst Target) | 217.5% | 227.4% | 40.6% | |
Fair Value Upside | Unlock | 10.9% | 5.3% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.000
(+212.50% Upside)
Earnings
Latest Release
Aug 11, 2025
EPS / Forecast
-0.40 / --
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Biocardia Trade On?
Biocardia is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Biocardia?
The stock symbol for Biocardia is "BCDA."
What Is the Biocardia Market Cap?
As of today, Biocardia market cap is 11.14M.
What Is Biocardia's Earnings Per Share (TTM)?
The Biocardia EPS (TTM) is -2.05.
From a Technical Analysis Perspective, Is BCDA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Biocardia Stock Split?
Biocardia has split 6 times.
How Many Employees Does Biocardia Have?
Biocardia has 19 employees.
What is the current trading status of Biocardia (BCDA)?
As of 15 Aug 2025, Biocardia (BCDA) is trading at a price of 1.92, with a previous close of 1.89. The stock has fluctuated within a day range of 1.87 to 1.95, while its 52-week range spans from 1.63 to 4.66.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.